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We have investigated the role of arachidonic acid metabolites in the 
regulation of interleukin-1 production by muri ne peri toneal macrophages. 
Indomethacin a potent inhibitor of prostaglandin synthesis caused a dose- 
dependent augmentation of lipopolysaccharide induced interleukin production (up 
to 7-fold at 5 PM). In contrast, lipoxygenase inhibitors, nordihydroguarietic 
acid and nafazatrom had no effect at doses that did not significantly decrease 
prostagl andi n synthesis. Added to lipopolysaccharide stimulated cultures, PGEZ 
suppressed interleukin in a dose-dependent manner. Zymosan induced i nterleuki n 
was al so augmented by indomethacin but unlike lipopolysaccharide treated 
cultures was suppressed by nordihydroguarietic acid. These data suggest that 
arachidonate metabolites may be potent autoregulators of macrophage inter- 
leukin-1 production. D 1985 Academic Press, Inc. 
Interleukin-1 (IL-l)* is being increasingly recognized as a important 
macrophage/monocyte-derived cytokine with effects on a wide variety of target 
tissues. Some of these effects include induction of fever (l), lymphocyte 
proliferation/maturation (2,3), the acute phase response (4), muscle catabolism 
(5) and fibroblast proliferation (6). 
While it is we1 1 known that numerous stimuli (e.g. endotoxin, immune 
complexes, phagocytosis etc) can induce IL-1 production by macrophages (7,8) 
there is little information regarding the factors which regulate its produc- 
tion. Considering the physiologic importance of this cytokine, especially in 
i nf 1 ammatory processes, such information might ultimately aid the therapeutic 
management of inflammatory disease. 
In the present paper we show augmentation of lipopolysaccharide 
induced IL-1 production by the cyclooxygenase inhibitor, indomethacin 
* 
Abbreviations used in this paper: 




nordi hydroguarieti c acid; LPS, lipopolysaccharide; CO, cyclooxygenase; LO, 
1 ipoxygenase. 
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and direct suppression by exogenously added prostaglandin PGE2. zymosan- 
induced IL-1 production was also augmented by INDO. Thus, we provide evidence 
for a model in which cyclooxygenase derived arachidonic acid metabolites act as 
feedback regulators of IL-1 production. 
MATERIALS AND METHODS 
Animals - Female, specific pathogen-free CBA/J mice (Jackson Laboratories, 
Bar Harbor, ME) were used in al 1 experiments. Mice were maintained under 
pathogen-free conditions and given food and water ad libitum. 
Macrophage cultures - Mouse resident peritoneal macrophages were obtained 
by peritoneal lavage with sterile RPMI-1640 (Grand Island Biological Co., Grand 
Island, NY). Cells were washed, counted, then suspended to ! l  x loo/ml RPM1 
with 5% fetal bovine serum (FBS) and 100 U penicillin and 100 ug strepto- 
myci n/ml. One ml of suspension was dispensed onto 35 mm sterile plastic 
culture dishes (Corning Glass Works, Corning, NY). After 2h incubation, (37O, 
5% co 
3’ 
100% humidity) nonadherent cells were removed by two vigorous rinses. 
he monolayers were overlaid with 1 ml of serum-free RPM1 with antibiotics 
plus the agent being tested for IL-1 induction, zymosan (500 c(g) or Salmonella 
lipopolysaccharide (10 ug) (Sigma Chemical Co., St. Louis, MO). Supernates 
were collected after 18h incubation. The total number of macrophages was 
quantitated by scraping cells from culture dishes and counting in a hemacytome- 
ter. These were >95% pure by morphology and phagocytic index. 
Arachidonic acid metabolites and metabolic inhibitors - Prostaglandi ns 
were kindly provided by Dr. J. Pike (Upjohn Co., Kalamazoo, Mich. ). Puritv of 
those compounds was checked by high pressure liquid chromatography-performed as 
previously described (9). 
Indomethacin and nordihydroguariatic acid were purchased from Sigma. 
Nafazatrom was kindly provided by Miles Laboratories, Elkhart, Ind. The in 
vitro specificity of these compounds in the inhibition of cyclooxygenase and 
lipoxygenase pathway has been previously published (10). 
Radioimmunoassay for prostaglandins - The macrophage culture medium was 
collected, centrifuged at 500 xg for 10 min and then subjected to radioimmuno- 
assay for PGE2 and 6-keto PGF 
cl” 
as described by Fitzpatrick et al. (11,12). 
Briefly, samples were extracte to remove protein and free fatty acids before 
addition of antibodies. Bound and free ligand were separated using dextran- 
coated charcoal. 
respectively. 
Sensitivity for PGE2 and 6-keto PGFlo were 8 and 4 picograms, 
Interleukin-1 assay - Interleukingl was measured by the standard thymocyte 
proliferation assay. Briefly, 5 x 10 mouse thymocytes in 0.1 ml RPMI-10% FBS 
containing 5 pg/ml PHA (Burroughs Welcome, Research Triangle, NC) were distrib- 
uted into each well of a 96-well sterile culture dish (Costar, Cambridge, 
Mass. ). Equal volumes of serially diluted test supernate were then added to 
triplicate wells. Control we1 1s contained no PHA. At 66h of incubation, the 
cells were pulsed with 0.5 pCi of tritiated thymidine then harvested at 72h. 
Total thymidine incorporation was determined by liquid scintillation spectro- 
photometry. Augmentation of PHA-induced thymocyte proliferation indicated IL-1 
activity. 
Statistical analysis - The Student’s t-test was used to compare control 
and experimental groups. Values of p > . 05 was considered not significant. 
RESULTS 
Effect of inhibitors of arachidonic acid metabolism on lipopolysaccharide- 
induced interleukin-1 production. Initially, we compared known inhibitors of 
cyclooxygenase (CO) and 1 ipoxygenase (LO) pathways of AA metabolism for their 
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Figure 1. Effect of inhibitors of arachidonic acid metabolism on LPS- 
induced IL-l production. Macrophaqe cultures (2.2 x 10 /dish) were 
stimulated 18h with LPS (10 pq/ml) in the presence of graded concen- 
trations of inhibitors. Supernates were then tested for IL-l activi- 
ty. Control macrophaqe cultures not stimulated with LPS qave the 
following values; no inhibitor, 714f401; 5 pM INDO, 773*357; 5 uM 
NDGA 986i286 ; 5 uM NAFAZ 699*289. Points are mean CPM f SD of 
triplicate determinations. 
Figure 2. Levels of prostaqlandins in LPS-stimulated macrophaqe cultures 
treated with various inhibitors of arachidonic acid metabolism. The 
culture supernates described in Figure 1 were tested by radioimmuno- 
assay for PGE2 and 6-keto-PGFlo, a spontaneous breakdown product of 
PG12 (prostacycl in). Points are mean of three determinations. 
effect on LPS-induced IL-l production. Figure 1 shows the dose-response 
kinetics of these compounds. A dose-dependent augmentation of IL-1 activity 
was obtained with the CO inhibitor, INDO, which caused a 7-fold increase at the 
5 pM concentration. In contrast, the LO inhibitors NDGA and nafazatrom had no 
significant effect over most of the dose range. However, a Z-fold augmentation 
was caused by NDGA at 5 HM. Interestingly, the augmentation of IL-1 activity 
was consistently inversely related to the levels of PGE2 and 6-keto-PGF1o (a 
breakdown product of prostacyclin) in the macrophage cultures (Figure 2). 
Effect of exogenous added PGE, on interleukin-1 production. We next 
c 
determined IL-l production in PGE2 treated LPS-stimulated macrophage cultures. 
As shown in Figure 3 (A & 6, closed circles) a dose dependent suppression Was 
observed. Moreover, the augmentation caused by INDO could be overcome by 
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? 
LPS-induced IL-l production. 
Macrophage cultures were stimu ated 18h with LPS (10 pg/ml) in the 
presence of graded concentrations of PGE2, then supernates were 
tested for IL-l activity. A. 
control 114i32. 
Suppression by PGE2. unstimulated 
8. Suppression by PGE2 in presence or absence of 
indomethacin (2.5 PM), unstimulated control 3982172. Points are mean 
cpm f SD of triplicate determinations. 
Effect of arachidonic acid metabolic inhibitors on 3zymosan- 
inducqd IL-l production. Percent change in IL-l activity ( H-thymi- 
dine uptake) produced by zymosan-stimulated macrophages in the 
presence of graded concentrations of indomethacin or NDGA. Points 
are mean % f SE of 3-5 experiments. 
exogenous PGE2 treatment (Figure 38, open circles). Thus, PGE2 could directly 
suppress IL-l production. 
Effect of inhibitors of arachidonic acid metabolism on zymosan-induced 
interleukin-1 production. When we tested CO and LO inhibitors for their effect 
on zymosan-induced IL-1 we again saw augmentation by INDO at 2.5 uM (Figure 4). 
However, this effect was less dramatic than when LPS was the stimulant. 
Furthermore, NDGA caused a definite suppression of zymosan-induced IL-1 at 2.5 
PM, an effect not observed when LPS was the stimulant. These data suggested 
that both CO and LO-derived metabolites may play a role in zymosan-induced IL-1 
synthesis. 
DISCUSSION 
It is well established that macrophages produce significant amounts of 
arachidonate metabolites as well as being a major source of IL-1 (13-Z). 
However, the relationship between these products is not understood. In the 
present report we provide direct and indirect evidence that products of the CO 
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pathway (PGE*, PG12) down-regulate the production of IL-1 by macrophages. Thus 
IL-1 synthesis may be profoundly affected by drugs which inhibit arachidonic 
acid metabolism (e.g. indomethacin). 
Our data imply a model of feedback regulation of IL-1 by prostaglandins. 
Interestingly, IL-1 can stimulate PGE2 synthesis in target tissues such as the 
hypothalamus and muscle (1,5). Hence, it demonstrates the classic characteris- 
tic of a hormone by inducing its own inhibitor. It is not clear as yet if IL-1 
plays a role in the induction of PG synthesis by macrophages, however studies 
to resolve this question are currently underway in our laboratory. The auto- 
regulatory effect of PG on IL-1 production is supported by the finding of 
Boraschi et al (16) showing that gamma-interferon can augment macrophage IL-1 -- 
production by suppression PGE2 release. 
Our finding that IL-1 production was more dramatically augmented by INDO 
in LPS-stimulated rather than zymosan-stimulated macrophages is most likely 
related to the differing spectra of AA metabolites induced by these stimuli. 
Stimulation with membrane perturbants such as LPS causes macrophages to release 
large amounts of essentially only CO products, PGE2 and PGI2, whereas zymosan 
stimulates production of lesser amounts of PGs as well as some leukotriene C4 
(LTC4) (17,18). We have confirmed this by high pressure liquid chromatographic 
analysis of our culture supernates. Furthermore, zymosan is not as potent as 
LPS in stimulating IL-l production. Thus, zymosan-stimulated macrophages may 
be under less tonic suppression by PGs. Moreover, we have recently reported 
that LTC4 can directly stimulate IL-1 production (19) and thus may oppose the 
suppressive effect of PGs. 
The potential stimulatory effect of LTC4 can also explain the observed 
suppressive effect of NDGA on zymosan-induced IL-l. The synthesis of LTC4, a 
lipoxygenase product, is blocked by NDGA. Hence, this would leave the suppres- 
sive action of PG unopposed as well as eliminate a stimulus of IL-1 production. 
It is noteworthy, that Dinarello et al. (2) have reported suppression of human 
monocyte IL-1 production (induced by a particulate stimulus) by lipoxygenase 
inhibitors, suggesting these mechanisms may also apply to humans. 
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In conclusion, we provide evidence that IL-1 production by macrophages is 
autoregulated by arachidonic acid metabolites i.e. suppressed by PGs. The 
degree of modulation appears to be affected by the nature of the inducing 
stimulus and possibly by presence of opposing stimuli such as lipoxygenase 
pathway metabol i tes. 
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